首页 > 最新文献

Infection and Chemotherapy最新文献

英文 中文
Late-Onset Granulomatous Pneumocystis jirovecii Pneumonia in A Renal Transplant Recipient: A Clinical Grand Round Conference Case in 2022. 肾移植受者晚期发作的吉氏肉芽肿性肺孢子虫肺炎:2022年一例临床大圆桌会议病例。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-09-01 DOI: 10.3947/ic.2023.0084
Yae Jee Baek, Kyeongmin Kim, Bo Da Nam, Jongtak Jung, Eunjung Lee, Hyunjin Noh, Tae Hyong Kim

Late-onset Pneumocystis jirovecii pneumonia (PCP) can be developed in solid organ transplant (SOT) patients. Granulomatous P. jirovecii pneumonia (GPCP) can occur in immunocompromised patients, but has rarely been reported in SOT recipients. The diagnosis of GPCP is difficult since the sensitivity of sputum and bronchoalveolar lavage is low and atypical patterns are shown. A 60-year-old man, who had undergone renal transplantation 24 years ago presented with nodular and patchy lung lesions. He was asymptomatic and stable. After empirical treatment with a fluoroquinolone, the condition partially resolved but relapsed 4 months later. The pulmonary nodule was resected, and GPCP was confirmed. The pathogenesis of GPCP remains unclear, but in SOT recipients presenting with an atypical lung pattern, GPCP should be considered. This case was discussed at the Grand Clinical Ground of the Korean Society of Infectious Disease conference on November 3, 2022.

迟发性吉氏肺孢子虫肺炎(PCP)可在实体器官移植(SOT)患者中发生。肉芽肿性吉氏疟原虫肺炎(GPCP)可发生在免疫功能低下的患者中,但很少在SOT接受者中报道。GPCP的诊断是困难的,因为痰和支气管肺泡灌洗的敏感性低,并且表现出非典型模式。一位60岁的男性,24年前接受了肾移植,肺部出现结节性和斑片状病变。他没有症状,病情稳定。经过氟喹诺酮类药物的经验性治疗,病情部分缓解,但4个月后复发。切除了肺结节,并确认了GPCP。GPCP的发病机制尚不清楚,但对于表现为非典型肺部模式的SOT受体,应考虑GPCP。该病例于2022年11月3日在韩国传染病学会大临床基地会议上进行了讨论。
{"title":"Late-Onset Granulomatous <i>Pneumocystis jirovecii</i> Pneumonia in A Renal Transplant Recipient: A Clinical Grand Round Conference Case in 2022.","authors":"Yae Jee Baek,&nbsp;Kyeongmin Kim,&nbsp;Bo Da Nam,&nbsp;Jongtak Jung,&nbsp;Eunjung Lee,&nbsp;Hyunjin Noh,&nbsp;Tae Hyong Kim","doi":"10.3947/ic.2023.0084","DOIUrl":"https://doi.org/10.3947/ic.2023.0084","url":null,"abstract":"<p><p>Late-onset <i>Pneumocystis jirovecii</i> pneumonia (PCP) can be developed in solid organ transplant (SOT) patients. Granulomatous <i>P. jirovecii</i> pneumonia (GPCP) can occur in immunocompromised patients, but has rarely been reported in SOT recipients. The diagnosis of GPCP is difficult since the sensitivity of sputum and bronchoalveolar lavage is low and atypical patterns are shown. A 60-year-old man, who had undergone renal transplantation 24 years ago presented with nodular and patchy lung lesions. He was asymptomatic and stable. After empirical treatment with a fluoroquinolone, the condition partially resolved but relapsed 4 months later. The pulmonary nodule was resected, and GPCP was confirmed. The pathogenesis of GPCP remains unclear, but in SOT recipients presenting with an atypical lung pattern, GPCP should be considered. This case was discussed at the Grand Clinical Ground of the Korean Society of Infectious Disease conference on November 3, 2022.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 3","pages":"309-316"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/5f/ic-55-309.PMC10551715.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41179280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1. 阿巴卡韦/多卢替拉韦/拉米夫定在HIV-1患者中的韩国上市后研究。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-09-01 Epub Date: 2023-05-04 DOI: 10.3947/ic.2022.0176
Sang-Kyu Shin, Jung-Eun Cho, Eun-Bin Lee, Yeon-Sook Kim, Sook-In Jung

Background: Abacavir/dolutegravir/lamivudine has been indicated in Korea since 2015 for treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination. This regulatory post-marketing surveillance (PMS) study evaluated the real-life safety and effectiveness of abacavir/dolutegravir/lamivudine in patients with HIV-1 in clinical practice in Korea.

Materials and methods: This open-label post-marketing surveillance examined data from consecutive patients (aged ≥12 years) with HIV-1 infection receiving abacavir/dolutegravir/lamivudine according to locally approved prescribing information; treatment-naïve and treatment-experienced patients were permitted. Data regarding patient demographics, medical history, clinical characteristics, medications (HIV-1 related and concomitant), resource utilization and comorbidities were extracted from patient records over a 1-year treatment period. Outcomes included safety of abacavir/dolutegravir/lamivudine (primary endpoint) and real-life effectiveness according to physician's global assessment and the proportion of patients with plasma HIV-1 RNA count <50 copies/mL at 48 weeks.

Results: Of 663 patients treated with abacavir/dolutegravir/lamivudine at 27 centers in Korea (June 2015 - June 2021), 656 were eligible for the safety analyses and 484 for effectiveness analyses. Patients were mostly male (94.8%) mean age was 42.2 ± 14.0 years and mean weight was 68.1 ± 11.0 kg. Adverse events (AEs, n = 656 in total) were mostly mild in severity, with the most common being nasopharyngitis (7.9%), retching (7.5%), headache (4.9%). Of 121 adverse drug reactions (ADRs), the most frequent were retching (4.4%), headache (1.8%) and dizziness (1.7%). Of 55 serious AEs, the most frequent were anogenital warts (1.1%). Of 2 serious ADRs, nothing was unexpected, and both resolved. The risk of experiencing an AE while receiving abacavir/dolutegravir/lamivudine appeared to be especially increased in patients receiving concomitant medications for other conditions. Abacavir/dolutegravir/lamivudine effectively suppressed HIV-1 (96.1% of patients had plasma HIV-1 RNA <50 copies/mL), and 99.0% of patients showed symptom improvement based on physician assessment.

Conclusion: Results of this PMS study showed that abacavir/dolutegravir/lamivudine administered as highly active antiretroviral therapy was well tolerated and effective in patients with HIV-1 infection.

背景:自2015年以来,阿巴卡韦/多卢替拉韦/拉米夫定已在韩国被用于联合治疗人类免疫缺陷病毒1型(HIV-1)感染。这项上市后监管监测(PMS)研究评估了在韩国临床实践中阿巴卡韦/多卢替拉韦/拉米夫定治疗HIV-1患者的真实安全性和有效性。材料和方法:这项开放标签上市后监测检查了根据当地批准的处方信息;治疗幼稚和治疗经验丰富的患者被允许。在一年的治疗期内,从患者记录中提取了有关患者人口统计、病史、临床特征、药物(HIV-1相关和伴随)、资源利用率和合并症的数据。根据医生的全球评估和血浆HIV-1 RNA计数患者的比例,结果包括阿巴卡韦/多卢替格拉韦/拉米夫定的安全性(主要终点)和现实有效性,656人符合安全性分析条件,484人符合有效性分析条件。患者多为男性(94.8%),平均年龄42.2±14.0岁,平均体重68.1±11.0 kg。不良事件(AE,共656例)严重程度较轻,最常见的是鼻咽炎(7.9%)、干呕(7.5%)、头痛(4.9%),最常见的是肛门生殖器疣(1.1%)。在2例严重的ADR中,没有什么意外,两例都得到了解决。在接受阿巴卡韦/多卢替拉韦/拉米夫定联合用药治疗的患者中,出现AE的风险似乎尤其增加。阿巴卡韦/多卢替拉韦/拉米夫定有效抑制HIV-1(96.1%的患者具有血浆HIV-1 RNA)。
{"title":"A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1.","authors":"Sang-Kyu Shin, Jung-Eun Cho, Eun-Bin Lee, Yeon-Sook Kim, Sook-In Jung","doi":"10.3947/ic.2022.0176","DOIUrl":"10.3947/ic.2022.0176","url":null,"abstract":"<p><strong>Background: </strong>Abacavir/dolutegravir/lamivudine has been indicated in Korea since 2015 for treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination. This regulatory post-marketing surveillance (PMS) study evaluated the real-life safety and effectiveness of abacavir/dolutegravir/lamivudine in patients with HIV-1 in clinical practice in Korea.</p><p><strong>Materials and methods: </strong>This open-label post-marketing surveillance examined data from consecutive patients (aged ≥12 years) with HIV-1 infection receiving abacavir/dolutegravir/lamivudine according to locally approved prescribing information; treatment-naïve and treatment-experienced patients were permitted. Data regarding patient demographics, medical history, clinical characteristics, medications (HIV-1 related and concomitant), resource utilization and comorbidities were extracted from patient records over a 1-year treatment period. Outcomes included safety of abacavir/dolutegravir/lamivudine (primary endpoint) and real-life effectiveness according to physician's global assessment and the proportion of patients with plasma HIV-1 RNA count <50 copies/mL at 48 weeks.</p><p><strong>Results: </strong>Of 663 patients treated with abacavir/dolutegravir/lamivudine at 27 centers in Korea (June 2015 - June 2021), 656 were eligible for the safety analyses and 484 for effectiveness analyses. Patients were mostly male (94.8%) mean age was 42.2 ± 14.0 years and mean weight was 68.1 ± 11.0 kg. Adverse events (AEs, n = 656 in total) were mostly mild in severity, with the most common being nasopharyngitis (7.9%), retching (7.5%), headache (4.9%). Of 121 adverse drug reactions (ADRs), the most frequent were retching (4.4%), headache (1.8%) and dizziness (1.7%). Of 55 serious AEs, the most frequent were anogenital warts (1.1%). Of 2 serious ADRs, nothing was unexpected, and both resolved. The risk of experiencing an AE while receiving abacavir/dolutegravir/lamivudine appeared to be especially increased in patients receiving concomitant medications for other conditions. Abacavir/dolutegravir/lamivudine effectively suppressed HIV-1 (96.1% of patients had plasma HIV-1 RNA <50 copies/mL), and 99.0% of patients showed symptom improvement based on physician assessment.</p><p><strong>Conclusion: </strong>Results of this PMS study showed that abacavir/dolutegravir/lamivudine administered as highly active antiretroviral therapy was well tolerated and effective in patients with HIV-1 infection.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"337-345"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/42/ic-55-337.PMC10551717.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9573764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resistance Trends of Antiretroviral Agents in People with Human Immunodeficiency Virus in Korea, 2012 - 2020. 2012-2020年韩国人类免疫缺陷病毒感染者抗逆转录病毒药物耐药性趋势。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-09-01 Epub Date: 2023-05-04 DOI: 10.3947/ic.2022.0150
Sang-Min Oh, Ji Hwan Bang, Sang-Won Park, Eunyoung Lee

Background: Domestic data on antiretroviral drug (ARV) resistance are limited, while alterations in ARV resistance are expected as the incidence of human immunodeficiency virus (HIV) infection increases. We evaluated the ten-year change in ARV resistance in people with HIV (PWH) in Korea.

Materials and methods: Adults aged ≥19 years and diagnosed with HIV infection between January 2010 and December 2020 at a 750-bed municipal hospital were retrospectively reviewed. Data on clinical characteristics and resistance mutation test results were collected. The study population was divided into three-year intervals according to diagnosed year and their clinical characteristics were compared.

Results: A total of 248 PWH were analyzed, and ARV resistance was detected in 30 of them (12.1%). Resistance was detected most frequently in PWH aged ≤29 years (16, 6.5%), and the median percentage of resistance detection per year was 14.3% (interquartile range, 12.7 - 16.1). The trend of the overall prevalence of ARV resistance mutations slightly decreased and then increased over time (15.3% in 2012 - 2014, 9.6% in 2015 - 2017, and 12.9% in 2018 - 2020). The prevalence of the non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance markedly decreased over time (15.3% in 2012 - 2014, 8.7% in 2015 - 2017, and 2.4% in 2018-2020), while that of protease inhibitor (PI) and integrase strand transfer inhibitor (INSTI) increased from 0 until 2018 to 3.5% and 8.2% in 2018 - 2020, respectively.

Conclusion: The trend of NNRTI resistance has decreased over time, and resistance to PIs and INSTIs increased from 2018. Therefore, continuous monitoring of ARV resistance pattern is necessary.

背景:关于抗逆转录病毒药物耐药性的国内数据有限,而随着人类免疫缺陷病毒感染率的增加,抗逆转录病毒耐药性预计会发生变化。我们评估了韩国HIV感染者抗逆转录病毒药物耐药性的十年变化。材料和方法:对2010年1月至2020年12月在一家拥有750张床位的市级医院诊断为HIV感染的年龄≥19岁的成年人进行回顾性审查。收集有关临床特征和耐药性突变试验结果的数据。研究人群根据诊断年份分为三年,并比较其临床特征。结果:共分析248例PWH,其中30例(12.1%)检出ARV耐药性,其中≤29岁PWH检出率最高(16,6.5%),每年耐药性检测的中位百分比为14.3%(四分位间距,12.7-16.1)。抗逆转录病毒耐药性突变的总体流行率随着时间的推移略有下降,然后上升(2012-2014年为15.3%,2015-2017年为9.6%,2018-2020年为12.9%)。随着时间的推移,非核苷逆转录酶抑制剂(NNRTI)耐药性的发生率显著下降(2012-2014年为15.3%,2015-2017年为8.7%,2018-2020年为2.4%),而蛋白酶抑制剂(PI)和整合酶链转移抑制剂(INSTI)的发生率从2018年的0分别上升到2018-2020年间的3.5%和8.2%。结论:随着时间的推移,NNRTI耐药性呈下降趋势,自2018年以来,对PIs和INSTI的耐药性有所增加。因此,有必要对抗逆转录病毒药物的耐药性模式进行持续监测。
{"title":"Resistance Trends of Antiretroviral Agents in People with Human Immunodeficiency Virus in Korea, 2012 - 2020.","authors":"Sang-Min Oh,&nbsp;Ji Hwan Bang,&nbsp;Sang-Won Park,&nbsp;Eunyoung Lee","doi":"10.3947/ic.2022.0150","DOIUrl":"10.3947/ic.2022.0150","url":null,"abstract":"<p><strong>Background: </strong>Domestic data on antiretroviral drug (ARV) resistance are limited, while alterations in ARV resistance are expected as the incidence of human immunodeficiency virus (HIV) infection increases. We evaluated the ten-year change in ARV resistance in people with HIV (PWH) in Korea.</p><p><strong>Materials and methods: </strong>Adults aged ≥19 years and diagnosed with HIV infection between January 2010 and December 2020 at a 750-bed municipal hospital were retrospectively reviewed. Data on clinical characteristics and resistance mutation test results were collected. The study population was divided into three-year intervals according to diagnosed year and their clinical characteristics were compared.</p><p><strong>Results: </strong>A total of 248 PWH were analyzed, and ARV resistance was detected in 30 of them (12.1%). Resistance was detected most frequently in PWH aged ≤29 years (16, 6.5%), and the median percentage of resistance detection per year was 14.3% (interquartile range, 12.7 - 16.1). The trend of the overall prevalence of ARV resistance mutations slightly decreased and then increased over time (15.3% in 2012 - 2014, 9.6% in 2015 - 2017, and 12.9% in 2018 - 2020). The prevalence of the non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance markedly decreased over time (15.3% in 2012 - 2014, 8.7% in 2015 - 2017, and 2.4% in 2018-2020), while that of protease inhibitor (PI) and integrase strand transfer inhibitor (INSTI) increased from 0 until 2018 to 3.5% and 8.2% in 2018 - 2020, respectively.</p><p><strong>Conclusion: </strong>The trend of NNRTI resistance has decreased over time, and resistance to PIs and INSTIs increased from 2018. Therefore, continuous monitoring of ARV resistance pattern is necessary.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"328-336"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/89/ic-55-328.PMC10551708.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9573765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Norovirus Infection in Children with Acute Lymphoblastic Leukemia. 儿童急性淋巴细胞白血病的诺如病毒感染。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-09-01 DOI: 10.3947/ic.2023.0058
Nalla Anuraag Reddy, Keerthi Raj, Harsha Prasada Lashkari

Norovirus infection in children on treatment for acute lymphoblastic leukemia can lead to severe morbidity due to chronic viral shedding, malabsorption, failure to thrive, and interruption of chemotherapy. We had four children with norovirus diarrhoea in eight years period in our pediatric oncology unit. Three children under two years of age had chronic noroviral shedding and persistent diarrhoea, probably due to poor adaptive immune responses. Two of those children didn't respond to nitazoxanide and succumbed to the illness. The third patient who received nitazoxanide and favipiravir, is currently well on chemotherapy.

在接受急性淋巴细胞白血病治疗的儿童中,诺如病毒感染可因慢性病毒脱落、吸收不良、发育不良和化疗中断而导致严重发病。我们的儿科肿瘤科在八年的时间里有四个患有诺如病毒腹泻的孩子。三名两岁以下儿童患有慢性诺如病毒脱落和持续腹泻,可能是由于适应性免疫反应差。其中两名儿童对硝唑嗪没有反应,最终死于该病。第三名患者接受了硝唑嗪和法匹拉韦治疗,目前正在接受良好的化疗。
{"title":"Norovirus Infection in Children with Acute Lymphoblastic Leukemia.","authors":"Nalla Anuraag Reddy,&nbsp;Keerthi Raj,&nbsp;Harsha Prasada Lashkari","doi":"10.3947/ic.2023.0058","DOIUrl":"https://doi.org/10.3947/ic.2023.0058","url":null,"abstract":"<p><p>Norovirus infection in children on treatment for acute lymphoblastic leukemia can lead to severe morbidity due to chronic viral shedding, malabsorption, failure to thrive, and interruption of chemotherapy. We had four children with norovirus diarrhoea in eight years period in our pediatric oncology unit. Three children under two years of age had chronic noroviral shedding and persistent diarrhoea, probably due to poor adaptive immune responses. Two of those children didn't respond to nitazoxanide and succumbed to the illness. The third patient who received nitazoxanide and favipiravir, is currently well on chemotherapy.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 3","pages":"403-407"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6f/95/ic-55-403.PMC10551709.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41123442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Cancer Service Delivery in the Philippines during the COVID-19 Pandemic. 新冠肺炎大流行期间菲律宾癌症服务提供。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-09-01 DOI: 10.3947/ic.2023.0081
Dalmacito A Cordero
{"title":"Cancer Service Delivery in the Philippines during the COVID-19 Pandemic.","authors":"Dalmacito A Cordero","doi":"10.3947/ic.2023.0081","DOIUrl":"10.3947/ic.2023.0081","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 3","pages":"408-409"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/ed/ic-55-408.PMC10551721.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41152037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiologic and Clinical Characteristics of Patients with Severe Fever with Thrombocytopenia Syndrome at Tertiary Hospital in Jeju for 10 years. 济州三级医院10年来严重发热伴血小板减少综合征患者的流行病学和临床特征。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-09-01 Epub Date: 2023-06-13 DOI: 10.3947/ic.2023.0035
Jae Yeon Kim, Jeong Rae Yoo, Misun Kim, Hyunjoo Oh, Sang Taek Heo

Background: Severe fever with thrombocytopenia syndrome (SFTS), which was first discovered in China in 2009, is an infectious disease with a high mortality rate, particularly in East Asia. This study aimed to investigate the epidemiological and clinical characteristics and risk factors for mortality by analyzing SFTS cases accumulated for up to ten years in Jeju, Korea.

Materials and methods: Medical records of patients diagnosed with SFTS between March 2013 and August 2022 at a tertiary hospital in Jeju were analyzed retrospectively. We investigated data of patients with SFTS on the epidemiologic and clinical characteristics, laboratory findings, and administered treatments and compared the differences between fatal and non-fatal groups.

Results: We enrolled 91 SFTS-confirmed patients. The median age of patients was 62 years, and the fatality rate increased with age (P = 0.004). Fever was the most common symptom (84.6%), and diarrhea (37.4%) was also present in some cases. The overall fatality rate was 10.9%. Dyspnea (20.0% vs. 0.0%, P = 0.009) and changes in mental status (70.0% vs. 11.0%, P <0.001) were more frequent in fatal cases. Risk factor assessment revealed that a high aspartate aminotransferase /alanine aminotransferase ratio (odds ratio [OR]: 39.568, 95% confidence interval [CI]: 1.479 - 1,058.639, P = 0.028) and elevated total bilirubin levels (OR: 53.037, 95% CI: 1.064 - 2,643.142, P = 0.046) were also significantly associated with fatal cases. Plasma exchange (40.7%) was the most commonly administered treatment.

Conclusion: SFTS has a high mortality rate; therefore, awareness of SFTS must be raised among physicians and citizens living in tick-inhabited areas, such as Jeju.

背景:2009年在中国首次发现的严重发热伴血小板减少综合征(SFTS)是一种死亡率很高的传染病,在东亚地区尤为严重。本研究旨在通过分析韩国济州市10年来累积的SFTS病例,调查流行病学和临床特征以及死亡率的危险因素。材料和方法:回顾性分析2013年3月至2022年8月在济州一家三级医院诊断为SFTS的患者的医疗记录。我们调查了SFTS患者的流行病学和临床特征、实验室发现和给药治疗数据,并比较了致命组和非致命组之间的差异。结果:我们招募了91名SFTS确诊患者。患者的中位年龄为62岁,死亡率随着年龄的增长而增加(P=0.004)。发烧是最常见的症状(84.6%),一些病例还出现腹泻(37.4%)。总病死率为10.9%。呼吸困难(20.0%vs.0.0%,P=0.009)、精神状态变化(70.0%vs.11.0%,P=0.028)和总胆红素水平升高(OR:53.037,95%CI:1.064-2643.142,P=0.046)也与死亡病例显著相关。血浆置换(40.7%)是最常用的治疗方法。结论:SFTS死亡率高;因此,必须提高医生和居住在蜱虫聚居区(如济州)的公民对SFTS的认识。
{"title":"Epidemiologic and Clinical Characteristics of Patients with Severe Fever with Thrombocytopenia Syndrome at Tertiary Hospital in Jeju for 10 years.","authors":"Jae Yeon Kim,&nbsp;Jeong Rae Yoo,&nbsp;Misun Kim,&nbsp;Hyunjoo Oh,&nbsp;Sang Taek Heo","doi":"10.3947/ic.2023.0035","DOIUrl":"10.3947/ic.2023.0035","url":null,"abstract":"<p><strong>Background: </strong>Severe fever with thrombocytopenia syndrome (SFTS), which was first discovered in China in 2009, is an infectious disease with a high mortality rate, particularly in East Asia. This study aimed to investigate the epidemiological and clinical characteristics and risk factors for mortality by analyzing SFTS cases accumulated for up to ten years in Jeju, Korea.</p><p><strong>Materials and methods: </strong>Medical records of patients diagnosed with SFTS between March 2013 and August 2022 at a tertiary hospital in Jeju were analyzed retrospectively. We investigated data of patients with SFTS on the epidemiologic and clinical characteristics, laboratory findings, and administered treatments and compared the differences between fatal and non-fatal groups.</p><p><strong>Results: </strong>We enrolled 91 SFTS-confirmed patients. The median age of patients was 62 years, and the fatality rate increased with age (<i>P</i> = 0.004). Fever was the most common symptom (84.6%), and diarrhea (37.4%) was also present in some cases. The overall fatality rate was 10.9%. Dyspnea (20.0% <i>vs.</i> 0.0%, <i>P</i> = 0.009) and changes in mental status (70.0% <i>vs.</i> 11.0%, <i>P</i> <0.001) were more frequent in fatal cases. Risk factor assessment revealed that a high aspartate aminotransferase /alanine aminotransferase ratio (odds ratio [OR]: 39.568, 95% confidence interval [CI]: 1.479 - 1,058.639, <i>P</i> = 0.028) and elevated total bilirubin levels (OR: 53.037, 95% CI: 1.064 - 2,643.142, <i>P</i> = 0.046) were also significantly associated with fatal cases. Plasma exchange (40.7%) was the most commonly administered treatment.</p><p><strong>Conclusion: </strong>SFTS has a high mortality rate; therefore, awareness of SFTS must be raised among physicians and citizens living in tick-inhabited areas, such as Jeju.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"377-387"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/bc/ic-55-377.PMC10551713.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10242530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seroprevalence of Measles IgG Antibodies in Married Immigrant Women from Multicultural Families in Korea. 韩国多文化家庭已婚移民妇女麻疹IgG抗体的血清流行率。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-09-01 Epub Date: 2023-06-14 DOI: 10.3947/ic.2023.0026
Woojoo Lee, Mi Yeong Shin, Eunbyeul Go, Hyun-Cheol Lim, Ji-Yoon Jeon, Yerim Kwon, Yerin Lee, Tong-Soo Kim, Sung-Keun Lee, Young Yil Bahk

Background: Although an effective vaccine has been available, measles still causes mast morbidity and mortality world widely. In Korea, a small number of measles cases have been reported through exposure to imported cases among young people with vaccine-induced measles immunity. Recently due to international migration including marriage, marriage migrants were the second-largest group of foreign population in Korea. Our study was carried out to obtain positive rate of measles antibody among married immigrant women from 12 countries in 10 Gun-Counties and 6 Cities, Korea.

Materials and methods: A total of 547 blood samples were collected from maternal multicultural members from 12 countries. The measles-specific IgG antibody was measured by ELISA (Enzyme-linked immunosorbent assay; Enzygnost® Anti-measles virus/IgG, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany). We performed a simple logistic regression to test whether the measles antibody seroprevalence differed by participant age, location, or country of birth and then calculated the likelihood ratio statistics to determine whether measles antibody seroprevalence differed by country of birth.

Results: Overall positive measles seroprevalence was 75.3% (95% confidence interval: 71.7 - 78.9). Participants aged 20 - 24 years, 25 - 29 years, and 30 - 63 years has respective seropositivities of 52.5%, 55.3%, and 82.7%. In this study, the geometric mean titers of participants aged 21 - 29 years were slightly lower than those of participants aged over 30 years, which were 1,372 mIU/ml and 2,261 mIU/ml, respectively (average of total participants: 2,027 mIU/ml).

Conclusion: The study provides detailed information about seroimmunity of the married immigrant population in Korea, which is important for measles elimination. Since the 1980s, most vaccine-preventable diseases including measles have been well-controlled. Nevertheless, sporadic measles outbreaks are still reported. Thus, special attention should be paid to the possible importation of infectious diseases such as measles by immigration.

背景:尽管已经有了有效的疫苗,但麻疹仍然会在世界范围内造成严重的发病率和死亡率。在韩国,有少量麻疹病例是通过在具有疫苗诱导的麻疹免疫力的年轻人中接触输入病例报告的。最近,由于包括婚姻在内的国际移民,婚姻移民成为韩国第二大外国人口群体。我们的研究是为了获得来自韩国10个郡和6个城市的12个国家的已婚移民妇女的麻疹抗体阳性率。材料和方法:共从来自12个国家的母亲多元文化成员中采集547份血液样本。麻疹特异性IgG抗体通过ELISA(酶联免疫吸附试验;Enzygnost®抗麻疹病毒/IgG,西门子医疗诊断产品有限公司,德国马尔堡)进行测量。我们进行了简单的逻辑回归,以测试麻疹抗体血清流行率是否因参与者年龄、地点或出生国而异,然后计算似然比统计数据,以确定麻疹抗体血清盛行率是否因出生国而异。结果:麻疹总阳性率为75.3%(95%置信区间:71.7-78.9)。20-24岁、25-29岁和30-63岁的参与者血清阳性率分别为52.5%、55.3%和82.7%。本研究中,21-29岁参与者的几何平均滴度略低于30岁以上参与者,分别为1372mIU/ml和2261mIU/ml(总参与者的平均值:2027mIU/ml)。结论:本研究提供了韩国已婚移民人群血清免疫的详细信息,对消除麻疹具有重要意义。自20世纪80年代以来,包括麻疹在内的大多数疫苗可预防的疾病都得到了很好的控制。尽管如此,仍有零星麻疹爆发的报告。因此,应特别注意移民可能输入麻疹等传染病。
{"title":"Seroprevalence of Measles IgG Antibodies in Married Immigrant Women from Multicultural Families in Korea.","authors":"Woojoo Lee,&nbsp;Mi Yeong Shin,&nbsp;Eunbyeul Go,&nbsp;Hyun-Cheol Lim,&nbsp;Ji-Yoon Jeon,&nbsp;Yerim Kwon,&nbsp;Yerin Lee,&nbsp;Tong-Soo Kim,&nbsp;Sung-Keun Lee,&nbsp;Young Yil Bahk","doi":"10.3947/ic.2023.0026","DOIUrl":"10.3947/ic.2023.0026","url":null,"abstract":"<p><strong>Background: </strong>Although an effective vaccine has been available, measles still causes mast morbidity and mortality world widely. In Korea, a small number of measles cases have been reported through exposure to imported cases among young people with vaccine-induced measles immunity. Recently due to international migration including marriage, marriage migrants were the second-largest group of foreign population in Korea. Our study was carried out to obtain positive rate of measles antibody among married immigrant women from 12 countries in 10 Gun-Counties and 6 Cities, Korea.</p><p><strong>Materials and methods: </strong>A total of 547 blood samples were collected from maternal multicultural members from 12 countries. The measles-specific IgG antibody was measured by ELISA (Enzyme-linked immunosorbent assay; Enzygnost<sup>®</sup> Anti-measles virus/IgG, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany). We performed a simple logistic regression to test whether the measles antibody seroprevalence differed by participant age, location, or country of birth and then calculated the likelihood ratio statistics to determine whether measles antibody seroprevalence differed by country of birth.</p><p><strong>Results: </strong>Overall positive measles seroprevalence was 75.3% (95% confidence interval: 71.7 - 78.9). Participants aged 20 - 24 years, 25 - 29 years, and 30 - 63 years has respective seropositivities of 52.5%, 55.3%, and 82.7%. In this study, the geometric mean titers of participants aged 21 - 29 years were slightly lower than those of participants aged over 30 years, which were 1,372 mIU/ml and 2,261 mIU/ml, respectively (average of total participants: 2,027 mIU/ml).</p><p><strong>Conclusion: </strong>The study provides detailed information about seroimmunity of the married immigrant population in Korea, which is important for measles elimination. Since the 1980s, most vaccine-preventable diseases including measles have been well-controlled. Nevertheless, sporadic measles outbreaks are still reported. Thus, special attention should be paid to the possible importation of infectious diseases such as measles by immigration.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"368-376"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/c0/ic-55-368.PMC10551720.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10259990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying the Unmet Medical Needs of HIV-Positive Subjects in Korea: Results of a Nationwide Online Survey. 确定韩国HIV阳性受试者未满足的医疗需求:全国在线调查结果。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-09-01 DOI: 10.3947/ic.2023.0065
Jeong-A Lee, Yeni Kim, Joo Yeon Lee, Sejun Park, Jun-Yong Choi

An online survey was conducted in Korea to identify the unmet medical needs of people living with human immunodeficiency virus (HIV) (PLWH). Participants (n = 105) were mostly male (93.3%), aged >40 years (75.2%), and treated for ≥6 years post-diagnosis (61.9%). Most PLWH (71.4%) were very satisfied/satisfied with their HIV management. Areas of concern were quality of life (QoL) and mental health. Characteristics of a long-term therapeutic agent were 'low risk of resistance', 'high long-term viral suppression efficacy', and 'high degree of safety'. Pre-consultation QoL and mental health screening would be beneficial for the long-term success of HIV management.

在韩国进行了一项在线调查,以确定人类免疫缺陷病毒(HIV)感染者未满足的医疗需求。参与者(n=105)大多为男性(93.3%),年龄>40岁(75.2%),诊断后治疗时间≥6年(61.9%)。大多数PLWH(71.4%)对其HIV管理非常满意。关注的领域是生活质量和心理健康。长期治疗剂的特点是“耐药性风险低”、“长期病毒抑制效果高”和“安全性高”。咨询前生活质量和心理健康筛查将有利于艾滋病管理的长期成功。
{"title":"Identifying the Unmet Medical Needs of HIV-Positive Subjects in Korea: Results of a Nationwide Online Survey.","authors":"Jeong-A Lee,&nbsp;Yeni Kim,&nbsp;Joo Yeon Lee,&nbsp;Sejun Park,&nbsp;Jun-Yong Choi","doi":"10.3947/ic.2023.0065","DOIUrl":"10.3947/ic.2023.0065","url":null,"abstract":"<p><p>An online survey was conducted in Korea to identify the unmet medical needs of people living with human immunodeficiency virus (HIV) (PLWH). Participants (n = 105) were mostly male (93.3%), aged >40 years (75.2%), and treated for ≥6 years post-diagnosis (61.9%). Most PLWH (71.4%) were very satisfied/satisfied with their HIV management. Areas of concern were quality of life (QoL) and mental health. Characteristics of a long-term therapeutic agent were 'low risk of resistance', 'high long-term viral suppression efficacy', and 'high degree of safety'. Pre-consultation QoL and mental health screening would be beneficial for the long-term success of HIV management.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 3","pages":"397-402"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/e5/ic-55-397.PMC10551716.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41140271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitigating from COVID-19 during Intercollegiate Sports Match. 在校际体育比赛期间缓解新冠肺炎。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-09-01 Epub Date: 2023-08-04 DOI: 10.3947/ic.2023.0047
Young June Choe, In Han Song, Kabsung Kim, Seunghun Hyun, Hee-Deung Park, Yun-Kyung Kim

The coronavirus disease 2019 pandemic has posed a significant threat not only to health outcomes but also to other societal sectors, including the educational system. Apart from youth education, colleges and universities are characterized by the integration of in-depth theoretical and practical knowledge in young adulthood. Our observations in this study suggest that college fairs, sports matches, and extracurricular activities can be safely resumed when population-level immunity has reached herd protection.

2019冠状病毒病大流行不仅对健康结果,而且对包括教育系统在内的其他社会部门构成了重大威胁。除了青年教育,高校的特点是在青年时期将深入的理论和实践知识相结合。我们在这项研究中的观察表明,当人群水平的免疫力达到群体保护时,大学博览会、体育比赛和课外活动可以安全地恢复。
{"title":"Mitigating from COVID-19 during Intercollegiate Sports Match.","authors":"Young June Choe,&nbsp;In Han Song,&nbsp;Kabsung Kim,&nbsp;Seunghun Hyun,&nbsp;Hee-Deung Park,&nbsp;Yun-Kyung Kim","doi":"10.3947/ic.2023.0047","DOIUrl":"10.3947/ic.2023.0047","url":null,"abstract":"<p><p>The coronavirus disease 2019 pandemic has posed a significant threat not only to health outcomes but also to other societal sectors, including the educational system. Apart from youth education, colleges and universities are characterized by the integration of in-depth theoretical and practical knowledge in young adulthood. Our observations in this study suggest that college fairs, sports matches, and extracurricular activities can be safely resumed when population-level immunity has reached herd protection.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"394-396"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/56/ic-55-394.PMC10551711.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10169905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility of Using Bacteriophage Therapy to Reduce Morbidity and Mortality Associated with Spinal Epidural Abscesses. 使用噬菌体治疗降低脊髓硬膜外脓肿发病率和死亡率的可行性。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-06-01 DOI: 10.3947/ic.2022.0168
James B Doub, Jeremy Tran, Ryan Smith, Tyler Pease, Eugene Koh, Stephen Ludwig, Alina Lee, Ben Chan

Background: The aim of this study was to determine the feasibility of using bacteriophage therapeutics in spinal epidural abscess (SEA) by reviewing the causes and outcomes of SEA at a single institution and testing a bacteriophage for activity against preserved SEA clinical isolates.

Materials and methods: Medical records were reviewed of patients that received incision and drainage for SEA at a single medical center. Causative organisms, incidence of coinciding bacteremia and outcomes were recorded. A subset of SEA patients (N = 11), that had preserved clinical isolates, were assessed to evaluate if a bacteriophage therapeutic had ample activity to those isolates as seen with spot tests and growth inhibition assays.

Results: Staphylococcus aureus was the predominate bacterial cause (71%) and bacteremia was associated with 96% of S. aureus SEA. Over 50% of the patients either died within three months, had recurrence of their infection, required repeat debridement, or had long term sequalae. A single bacteriophage had positive spot tests for all the S. aureus clinical isolates and inhibited bacterial growth for more than 24 hours for 9 of the 11 (82%) clinical isolates.

Conclusion: SEA is associated with significant mortality and morbidity making this a potential indication for adjuvant bacteriophage therapeutics. Since S. aureus is the predominate cause of SEA and most cases are associated bacteremia this creates a potential screening and treatment platform for Staphylococcal bacteriophages therapeutics, allowing for potential pilot studies to be devised.

背景:本研究的目的是通过回顾单个机构中脊髓硬膜外脓肿(SEA)的原因和结果,并测试噬菌体对保存的SEA临床分离物的活性,来确定使用噬菌体治疗脊髓硬膜外脓肿(SEA)的可行性。材料和方法:回顾了在同一医疗中心接受SEA切口引流的患者的医疗记录。记录致病菌、合并菌血症发生率和结果。对保留临床分离株的SEA患者(N = 11)进行评估,以评估噬菌体治疗是否对这些分离株有足够的活性,如现场试验和生长抑制试验所见。结果:金黄色葡萄球菌为主要病原菌(71%),96%的金黄色葡萄球菌SEA伴有菌血症。超过50%的患者在三个月内死亡,感染复发,需要反复清创,或有长期后遗症。单个噬菌体对所有金黄色葡萄球菌临床分离株的斑点试验均呈阳性,对11株临床分离株中的9株(82%)抑制细菌生长超过24小时。结论:SEA与显著的死亡率和发病率相关,使其成为辅助噬菌体治疗的潜在适应症。由于金黄色葡萄球菌是SEA的主要病因,并且大多数病例都伴有菌血症,这为葡萄球菌噬菌体治疗创造了一个潜在的筛选和治疗平台,从而允许设计潜在的试点研究。
{"title":"Feasibility of Using Bacteriophage Therapy to Reduce Morbidity and Mortality Associated with Spinal Epidural Abscesses.","authors":"James B Doub,&nbsp;Jeremy Tran,&nbsp;Ryan Smith,&nbsp;Tyler Pease,&nbsp;Eugene Koh,&nbsp;Stephen Ludwig,&nbsp;Alina Lee,&nbsp;Ben Chan","doi":"10.3947/ic.2022.0168","DOIUrl":"https://doi.org/10.3947/ic.2022.0168","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to determine the feasibility of using bacteriophage therapeutics in spinal epidural abscess (SEA) by reviewing the causes and outcomes of SEA at a single institution and testing a bacteriophage for activity against preserved SEA clinical isolates.</p><p><strong>Materials and methods: </strong>Medical records were reviewed of patients that received incision and drainage for SEA at a single medical center. Causative organisms, incidence of coinciding bacteremia and outcomes were recorded. A subset of SEA patients (N = 11), that had preserved clinical isolates, were assessed to evaluate if a bacteriophage therapeutic had ample activity to those isolates as seen with spot tests and growth inhibition assays.</p><p><strong>Results: </strong><i>Staphylococcus aureus</i> was the predominate bacterial cause (71%) and bacteremia was associated with 96% of <i>S. aureus</i> SEA. Over 50% of the patients either died within three months, had recurrence of their infection, required repeat debridement, or had long term sequalae. A single bacteriophage had positive spot tests for all the <i>S. aureus</i> clinical isolates and inhibited bacterial growth for more than 24 hours for 9 of the 11 (82%) clinical isolates.</p><p><strong>Conclusion: </strong>SEA is associated with significant mortality and morbidity making this a potential indication for adjuvant bacteriophage therapeutics. Since <i>S. aureus</i> is the predominate cause of SEA and most cases are associated bacteremia this creates a potential screening and treatment platform for Staphylococcal bacteriophages therapeutics, allowing for potential pilot studies to be devised.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 2","pages":"257-263"},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/e2/ic-55-257.PMC10323537.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10179854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Infection and Chemotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1